The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Regulatory News (PXS)

Share Price Information for Provexis (PXS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.60
Bid: 0.55
Ask: 0.65
Change: 0.00 (0.00%)
Spread: 0.10 (18.182%)
Open: 0.60
High: 0.00
Low: 0.00
Prev. Close: 0.60
PXS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Open Offer

3 Dec 2009 07:00

RNS Number : 5044D
Provexis PLC
03 December 2009
 



Provexis plc 

 

Open Offer of up to 85,211,664 new Ordinary Shares at 2.5 pence per share

on the basis of 1 Offer Share for every 12 Existing Shares with Excess Application Facility

The Board of Provexis today announces that it proposes to raise up to approximately £2.1 million (before expenses) by way of an Open Offer. The Open Offer follows the completion of the Subscription by the Company, as announced on 25 September 2009. The Company is able to undertake the Open Offer within the authorities that were approved by Shareholders at the annual general meeting of the Company held on 15 October 2009. There is no requirement for Shareholders to vote on the Open Offer. Qualifying Shareholders may subscribe for Offer Shares above their basic pro rata Open Offer Entitlements if they so wish under the Excess Application Facility. 

Reasons for the Open Offer

The Company announced on 25 September 2009 a subscription by new and existing shareholders of 200,000,000 new Ordinary Shares at a price of 2.5p per share to raise £5 million before commission and expenses. The subscription price represented a discount of approximately 72.2 per cent. to the closing mid-market price of 9 pence per Ordinary Share on 24 September 2009, being the last dealing day prior to the announcement of the Subscription. 

While the Directors believed the Subscription to be in the best interests of the Company and Shareholders as a whole, they considered it appropriate that all Shareholders should be offered the opportunity to participate at the same price per share as those subscribing for the Subscription. At the time of the Subscription an offer to existing Shareholders by way of a rights or other pre-emptive issue was not practicable or feasible due to the delays that would be incurred. 

Following the completion of the Subscription, the Directors are now able to proceed with an open offer to allow Shareholders to invest in the Company at the same price per share as those subscribing in the Subscription.

Details of the Open Offer

Qualifying Shareholders are invited to apply for Offer Shares under the Open Offer at a price of 2.5 pence per Offer Share, payable in full on application and free of all expenses, pro rata to their existing shareholdings on the basis of:

1 Offer Share for every 12 Existing Ordinary Shares

held at the Open Offer Record Date. Entitlements of Qualifying Shareholders will be rounded down to the nearest whole number of Offer Shares. Fractional entitlements which would have otherwise arisen will not be issued. The Open Offer is subject to Admission becoming effective by 8.00 a.m. 22 December 2009 (or such later date being not later than 8.00 a.m. on 30 December 2009, as the Company may decide). 

The Offer Shares will, when issued and fully paid, rank pari passu in all respects with the Existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid after the date of Admission. 

The Offer Shares have not been placed subject to clawback nor have they been underwritten. Consequently, there may be either no Offer Shares or fewer than 85,211,664 Offer Shares issued pursuant to the Open Offer. 

The Open Offer has been structured so as to allow Qualifying Shareholders to subscribe for Ordinary Shares at the Offer Price pro rata to their existing holdings. Qualifying Shareholders may, in addition, make applications in excess of their basic pro rata Open Offer Entitlements. Once subscriptions under the basic pro rata Open Offer Entitlements have been satisfied, the Company shall scale back any excess applications on a pro rata basis in proportion to the total number of Excess Shares applied for under the Excess Application Facility. To the extent that Offer Shares are not subscribed by Qualifying Shareholders, Open Offer entitlements will lapse. 

Subject to availability, the Excess Application Facility enables Qualifying Shareholders to apply for any whole number of Excess Shares in excess of their Basic Entitlement Qualifying Non-CREST Shareholders who wish to apply to subscribe for more than their Basic Entitlement should complete the relevant sections on the Non-CREST Application Form. Qualifying CREST Shareholders will have Excess CREST Open Offer Entitlements credited to their stock account in CREST. The Excess Application Facility enables Qualifying CREST Shareholders to apply for Excess Shares in excess of their Basic Entitlement up to a maximum number of Excess Shares equal to ninety times the number of Existing Shares registered in their name as at the Record DateIf however Qualifying CREST Shareholders wish to apply for more than ninety times the number of Existing Shares registered in their name as at the Record Date, up to the maximum number of shares available under the Open Offer the Qualifying CREST Shareholder should contact Equiniti directly. Excess applications may be allocated in such manner as the Directors determine, in their absolute discretion, and no assurance can be given that applications by Qualifying Shareholders under the Excess Application Facility will be met in full or in part or at all. 

PLEASE NOTE: Qualifying Shareholders can apply for as few or as many Offer Shares as they wish but will only be guaranteed to receive their basic pro rata Open Offer Entitlement. Excess applications may be fulfilled entirely or may be scaled back depending on Qualifying Shareholder demand.

Settlement and dealings

Application will be made to the London Stock Exchange for the Offer Shares to be admitted to trading on AIM. It is expected that such Admission will become effective and that dealings will commence on 22 December 2009.

Current trading

The Company has today announced its unaudited interim results for the six months ended 30 September 2009

Action to be taken in respect of the Open Offer

Shareholders (non-CREST)

Qualifying non-CREST Shareholders will be sent an Application Form which gives details of your basic Open Offer Entitlements (as shown by the number of basic pro rata Open Offer Entitlements allocated to you). If Qualifying non-CREST Shareholders wish to apply for Offer Shares under the Open Offer (including additional Excess Shares under the Excess Application Facility), they should complete this Application Form and post it in the accompanying prepaid envelope, together with payment in full in respect of the number of Offer Shares applied for to Equiniti, so as to arrive as soon as possible and in any event so as to be received no later than 11.00 a.m. on 21 December 2009.

Qualifying CREST Shareholders

No Application Form will be sent to Qualifying CREST Shareholders, they will receive a credit in their appropriate stock account in CREST in respect of the Open Offer Entitlements representing their basic Open Offer Entitlements and also in respect of their Excess CREST Open Offer Entitlements, except (subject to certain exceptions) if they are in the United States, or have a registered address in, or are resident in United States, Canada, Japan, Australia or the Republic of South Africa. If Qualifying CREST Shareholders wish to apply for more than their Excess CREST Open Offer Entitlement they should contact Equiniti directly.

Qualifying Shareholders can apply for as few or as many Offer Shares as they wish but will only be guaranteed to receive up to their basic pro rata Open Offer Entitlement. Excess applications may be fulfilled entirely or may be scaled back depending on Qualifying Shareholder demand. In the event Excess Applications are scaled back any excess monies will be returned to non-CREST Shareholders by cheque and to CREST Shareholders through CREST. 

Qualifying CREST Shareholders who are CREST sponsored members should refer to their CREST sponsors regarding the action to be taken in connection with the Open Offer.

Intentions of the Directors in relation to the Open Offer

A number of the Directors are Qualifying Shareholders and have committed themselves to apply to acquire Offer Shares pursuant to the Open Offer Entitlements attributable to their Existing Ordinary Shares. Details of the Directors' interests in the Existing Ordinary Shares and the number of Offer Shares they intend to subscribe for is set out in the table below:

Number of

Number of

Ordinary Shares

% of Enlarged

Existing

Number of

held

Issued

Ordinary

Offer Shares

following

Share Capital

Name of Director

Shares held

subscribed for

Admission

Mr. Dawson Buck*

10,404,332

867,027

11,271,359

1.0%

Dr. Neville Bain

5,177,000

431,416

5,608,416

0.5%

Mr. Stephen Moon

7,540,000

0

7,540,000

0.7%

Mr. Steven Morrison

1,540,000

128,333

1,668,333

0.2%

Mr. Ian Ford

1,540,000

128,333

1,668,333

0.2%

* Of the 10,404,332 Ordinary Shares that Mr Dawson Buck is interested in 3,581,666 are held by a pension scheme of which Mr Dawson Buck is the beneficiary and 1,540,000 are held by a pension scheme of which a member of the family of Mr Dawson Buck is the beneficiary. The remaining 5,282,666 Ordinary Shares are held directly by Mr Dawson Buck.

Recommendation

The Directors consider the Open Offer to be in the best interests of the Company and its Shareholders as a whole.

Availability of Circular 

 

The Circular setting out details of the Open Offer, accompanied by the Application Form (if applicable), is expected to be posted to Qualifying Shareholders today. 

 

Copies of the Circular will be available for a period of 12 months from the date of the Circular on the Company's website (www.provexis.com) free of charge in accordance with the requirements of Rule 26 of the AIM Rules.

Terms used in this announcement shall, unless the context otherwise requires, bear the meanings given to them in the Circular.

OPEN OFFER STATISTICS 

 

Market price Ordinary Share (1)
7.9 pence
Number of Ordinary Shares in issue at the date of this document
1,022,539,965
Offer Price
2.5 pence
Number of Offer Shares to be offered for subscription by the Company
85,211,664
Estimated maximum gross proceeds of the Open Offer (2)
£2.1 million
Number of Ordinary Shares in issue at Admission (2)
1,107,751,629

Percentage of the Enlarged Issue Share Capital represented bythe Offer Shares(2)

7.7%
 
 

(1) based on the closing mid-market price per Ordinary Shares on 1 December 2009, being the last practicable date prior to the announcement of the Open Offer

(2) assuming maximum take up under the Open Offer

EXPECTED TIMETABLE OF PRINCIPAL EVENTS

2009

Open Offer Record Date and time

5.00 p.m. on 1 December

Announcement of the Open Offer

 3 December

Existing Ordinary Shares marked 'ex' by the London Stock Exchange

3 December

Open Offer Entitlements credit to stock account in CREST of

Qualifying CREST Holders

3 December

Recommended latest time for requesting withdrawal of Open

Offer Entitlements from CREST

4.30 p.m. on 15 December

Latest time for depositing Open Offer Entitlements into CREST

3.00 p.m. on 16 December

Latest time and date for splitting of Application Forms

(to satisfy bona fide market claims only)

3.00 p.m. on 17 December

Latest time and date for receipt of completed Application Forms 

and payment in full under the Open Offer or settlement or relevant

CREST instruction (as appropriate)

11.00 a.m. on 21 December

Date of Admission and commencement of dealings of the Offer Shares

22 December

Offer Shares credited to CREST stock accounts

22 December

Date of despatch of definitive share certificates for Offer Shares

29 December

Notes:

(1) References to times in this document are to London time (unless otherwise stated).

(2) If any of the above times or dates should change, the revised times and/or dates will be notified by an announcement to an RIS.

(3) The timing of the events in the above timetable and in the rest of this document are indicative only.

3 December 2009

For further information please contact: 

Provexis plc  Tel: 01753 752290 

Stephen Moon, Chief Executive 

Evolution Securities Tel: 0207 071 4300 

Sam Plumptre 

Bobbie Hilliam

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCCKBKPOBDDPBK
Date   Source Headline
28th Mar 20247:00 amRNSIssue of Equity - purchase of Fruitflow® II SD
29th Dec 202312:48 pmRNSHalf-year Report
26th Oct 20231:51 pmRNSResult of AGM
29th Sep 20237:00 amRNSFinal Results
30th Aug 20237:04 amRNSBYHEALTH regulatory filing with Chinese SAMR
3rd Apr 20237:00 amRNSCapital structure and funding update
24th Jan 202311:03 amRNSGrant of Share Options
30th Dec 20228:53 amRNSHalf-year Report
27th Oct 20221:12 pmRNSResult of AGM
14th Oct 20227:00 amRNSDirectorate Change
30th Sep 20227:00 amRNSFinal Results
22nd Jun 20227:00 amRNSTwo new agreements with DSM & patent application
31st May 20225:00 pmRNSTotal Voting Rights
17th May 202212:39 pmRNSExercise of Options and Total Voting Rights
31st Dec 20217:00 amRNSHalf-year Report
26th Nov 20214:41 pmRNSSecond Price Monitoring Extn
26th Nov 20214:36 pmRNSPrice Monitoring Extension
4th Nov 20211:30 pmRNSResult of AGM
4th Nov 202111:07 amRNSBy-Health Fruitflow agreement and support in R&D
1st Oct 20216:04 pmRNSGrant of Share Options
30th Sep 20217:00 amRNSFinal Results
9th Sep 20214:41 pmRNSSecond Price Monitoring Extn
9th Sep 20214:35 pmRNSPrice Monitoring Extension
24th Aug 20214:35 pmRNSPrice Monitoring Extension
22nd Jul 20214:40 pmRNSSecond Price Monitoring Extn
22nd Jul 20214:35 pmRNSPrice Monitoring Extension
21st Jul 20214:41 pmRNSSecond Price Monitoring Extn
21st Jul 20214:36 pmRNSPrice Monitoring Extension
5th Jul 20214:35 pmRNSPrice Monitoring Extension
1st Jul 20214:40 pmRNSSecond Price Monitoring Extn
1st Jul 20214:35 pmRNSPrice Monitoring Extension
26th Feb 20215:00 pmRNSTotal Voting Rights
19th Feb 20217:30 amRNSDirector / PDMR notification
19th Feb 20217:00 amRNSPlacing of new ordinary shares to raise £50,000
29th Jan 202112:37 pmRNSHalf-year Report
31st Dec 20201:00 pmRNSTotal Voting Rights
17th Dec 20207:00 amRNS£1m placing & update re HY results
16th Nov 20207:00 amRNSExclusive Distribution Agreement for Chinese CBEC
30th Oct 20202:09 pmRNSResult of AGM
30th Sep 20207:00 amRNSFinal Results
28th Aug 20205:00 pmRNSTotal Voting Rights
13th Aug 20207:00 amRNSFruitflow® & Blood Pressure - purchase of IP
7th Aug 20205:11 pmRNSHolding(s) in Company
27th May 20207:00 amRNSHolding(s) in Company
31st Dec 20197:13 amRNSInterim Results and Total Voting Rights
11th Dec 20197:00 amRNSPlacing of new ordinary shares to raise £0.301m
4th Oct 20191:19 pmRNSResult of AGM
12th Sep 20193:19 pmRNSDirector/PDMR Shareholding
11th Sep 20194:02 pmRNSGrant of Share Options
10th Sep 20197:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.